Synlogic, Inc. (SYBX)
OTCMKTS · Delayed Price · Currency is USD
0.5650
-0.0062 (-1.09%)
At close: Jan 23, 2026
Synlogic Company Description
Synlogic, Inc., a biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States.
Its pipeline include SYNB1618 for the treatment of phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.
The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Winchester, Massachusetts.
Contact Details
Address: PO Box 30 Winchester, Massachusetts 01890 United States | |
| Phone | 617 659 2802 |
| Website | synlogictx.com |
Stock Details
| Ticker Symbol | SYBX |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US87166L1008 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Mary Beth Dooley | Principal Executive Officer and Principal Financial Officer |
| Dr. Timothy K. Lu M.D., Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Dr. James J. Collins Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Dr. Jose-Carlos Gutierrez-Ramos Ph.D. | Advisor |